Correction: The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. A meta-analysis and functional study


Figure 4 is amended to reflect the lack of definitive, controlled clinical evidence of prevention of structural progression by secukinumab in axial spondyloarthritis.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.